Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
Cancer Communications · 2025
DOI: 10.1002/cac2.12654 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, 2025. Verfasst von Tianqing Chu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Indoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Innovation Action Plan, Medical Innovation Research Special Project of Shanghai, Medical and Health Technology Development Research Center of the National Health Commission.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The prognosis for non‐small cell lung cancer (NSCLC) patients treated with standard platinum‐based chemotherapy was suboptimal, with safety concerns. Following encouraging results from a preliminary phase I study, this phase II trial investigated the efficacy and safety of first‐line sintilimab and anlotinib in metastatic NSCLC.
Methods
In this open‐label, randomized controlled trial (NCT04124731), metastatic NSCLC without epithelial growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto‐oncogene tyrosine‐protein kinase ROS (ROS1) mutations, and previous treatments for metastatic disease were enrolled. Participants were randomly assigned in a 1:1 ratio to either sintilimab (200 mg every 3 weeks) plus anlotinib (12 mg D1‐14 every 3 weeks) or a standard platinum‐based chemotherapy regimen. Patients in the chemotherapy group were permitted to switch to sintilimab after disease progression. The primary endpoint was the objective response rate (ORR).
Results
From November 2019 to March 2023, 99 patients were randomized into the sintilimab plus anlotinib group ( n = 49) and the chemotherapy group ( n = 50). The ORR was significantly higher in the sintilimab plus anlotinib group (44.9%; 95% confidence interval [CI] = 30.7%‐59.8%) compared to the chemotherapy group (18.0%; 95% CI = 8.6%‐31.4%, P = 0.003). Progression‐free survival (PFS) was also notably longer (median: 14.4 vs. 5.6 months; hazard ratio [HR] = 0.39; 95% CI = 0.23‐0.67; P < 0.001). The 24‐month overall survival rate was 58.4% (95% CI = 40.4%‐72.6%) and 43.2% (95% CI = 26.0%‐59.2%), respectively. The rate of grade 3 or higher treatment‐related adverse events was lower in the sintilimab plus anlotinib group (28.0%) than in the chemotherapy group (49.0%), especially for the hematological toxicities.
Conclusion
First‐line sintilimab plus anlotinib showed improved ORR and PFS, alongside a superior safety profile, compared to the standard platinum‐based chemotherapy for metastatic NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, P. R. China.
- Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, P. R. China.
- Department of Respiratory Medicine, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
- Department of Thoracic Oncology, Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.
- Department of Medical Oncology, Anhui Chest Hospital, Hefei, Anhui, P. R. China.
- Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, P. R. China.
ORCID-Profile: Baohui Han
Förderung
- Science and Technology Innovation Action Plan
- Medical Innovation Research Special Project of Shanghai
- Medical and Health Technology Development Research Center of the National Health Commission
Zitieren
APA
Chu, T., Zhong, H., Yu, Z., Wang, J., Zhao, Y., Mu, X., Yu, X., Shi, X., Shi, Q., Guan, M., Ding, C., Geng, N., Qian, J., & Han, B. (2025). Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial. Cancer Communications. https://doi.org/10.1002/cac2.12654
Vancouver
Chu T, Zhong H, Yu Z, Wang J, Zhao Y, Mu X, et al. Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial. Cancer Communications. 2025. doi:10.1002/cac2.12654
BibTeX
@article{Chu2025,
author = {Chu, Tianqing and Zhong, Hua and Yu, Zhuang and Wang, Jing and Zhao, Yanqiu and Mu, Xiaoqian and Yu, Xinmin and Shi, Xun and Shi, Qingming and Guan, Maojing and Ding, Cuimin and Geng, Nan and Qian, Jialin and Han, Baohui},
title = {Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial},
journal = {Cancer Communications},
year = {2025},
doi = {10.1002/cac2.12654}
}
EUVIMED